Capstan Therapeutics to Participate in SVB Securities 2023 Global Biopharma Conference
SAN DIEGO and PHILADELPHIA, January 24, 2023 – Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that Capstan management will participate in the upcoming SVB Securities 2023 Global Biopharma Conference, being held virtually between January 31- February 2 and February 13-16, 2023.
Capstan will participate in the private company exhibition taking place between January 31- February 2, 2023.
About Capstan (www.capstantx.com)
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body. The company is combining the power of cell therapy with the precision of genetic medicines to develop new treatment options for patients for oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. The Company is co-founded by pioneers in the field of CAR-based immunotherapy, nucleic acid drug delivery, tLNPs, and regenerative medicine, including experienced industry leaders, as well as academic faculty members from the University of Pennsylvania. Capstan has a bicoastal presence with operations in San Diego, CA and Philadelphia, PA. For more information, please visit www.capstantx.com and follow us on LinkedIn.
Investors:
Miguel Arcinas
Vice President of Corporate Development
Capstan Therapeutics
[email protected]
Media:
Rhiannon Jeselonis
Ten Bridge Communications
[email protected]